Market Cap 65.88M
Revenue (ttm) 0.00
Net Income (ttm) -95.49M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 4.23
Volume 1,482,200
Avg Vol 5,528,210
Day's Range N/A - N/A
Shares Out 65.88M
Stochastic %K 66%
Beta 0.21
Analysts Sell
Price Target $2.46

Company Profile

IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating therapeutic cancer vaccines based on the T-win technology platform. The company's lead therapeutic cancer vaccine candidate includes IO102-IO103, which targets cancer cells and immune-suppressive cells in the tumor microenvironment that express indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 3 clinical trial to treat melanoma, as well as in phase 2 clinical trial to...

Industry: Biotechnology
Sector: Healthcare
Phone: 45 70 70 29 80
Address:
Ole MaalOees Vej 3, Copenhagen N, Copenhagen, Denmark
UnicornProfits
UnicornProfits Oct. 24 at 8:37 PM
What is happening to ticker CMCT right now?! CMCT is breaking out like crazy.. only 700k float Are they pumping up ticker CMCT for 300% today!? Looks like all eyes are moving to CMCT now.. Watching: $IOBT $YYAI $TOVX $BBAI -!
0 · Reply
SnoddyTradz
SnoddyTradz Oct. 24 at 7:08 PM
$IOBT $YDKG $SCNX Check out $WGRX
0 · Reply
SnoddyTradz
SnoddyTradz Oct. 24 at 4:45 PM
$IOBT $DNUT $BYND $IXHL Check out $SCNX
0 · Reply
BadyBady
BadyBady Oct. 24 at 2:45 PM
$IOBT I Believe I can Fly 😎
0 · Reply
GCPA
GCPA Oct. 24 at 2:39 PM
$IOBT Acral/mucosal Melanoma patients were 24; pre-treated were 36. A total of 60 (ab 15% of ITT). Removing pre-treated, mPFS went to 24.8 months (HR 0.74); removing acral mucosal, mPFS went to 22.3 months. Both subgroups reduced mPFS equally. To remove both altogether should increase mPFS far beyond 25 months.
1 · Reply
BadyBady
BadyBady Oct. 24 at 1:25 PM
0 · Reply
BadyBady
BadyBady Oct. 24 at 9:14 AM
0 · Reply
BadyBady
BadyBady Oct. 24 at 9:08 AM
$IOBT Amazing potential 😎❤️😍
0 · Reply
GCPA
GCPA Oct. 23 at 11:22 PM
$IOBT Seeing DOR graph (about 42% of ITT population stll in response at 18 months and curve already flat in Cyl. arm) you see that OS can be stat. sig or very very close to it, even with the few number of events pre-specified in protocol. Market has seen that. Don't think at all that the Company will end bankrupt. BUT this trial has three issues. Two that we know (narrowly missed stat. sig in PE, and just 17 US patients). And a third one that I see clearly appearing now. Hassel said it in an interview, and it was also stated in a paper @badprecog posted. MOA is not fully clear, translational analysis needed: how did the effect happen in PDL1-? It wasn't clear in Phase 1/2. And, why did it work so bad in PDL1+ if in H&N has worked so well in PDL1+ -even lung has been better? Too much noise and two subgroups to extract in a new trial: pretreated (9% of patients) and acral-mucosal (ab 5% of patients). If OS hits, may be Conditional marketing by EMA with a confirmatory trial.
1 · Reply
Nieven
Nieven Oct. 23 at 8:00 PM
0 · Reply
Latest News on IOBT
IO Biotech Provides Update Following Pre-BLA Meeting with FDA

Sep 29, 2025, 7:05 AM EDT - 26 days ago

IO Biotech Provides Update Following Pre-BLA Meeting with FDA


IO Biotech Reports 2024 Business Highlights

Mar 4, 2025, 4:17 PM EST - 8 months ago

IO Biotech Reports 2024 Business Highlights


IO Biotech: A Phase 3 Company Getting No Respect

Jan 3, 2024, 3:04 AM EST - 1 year ago

IO Biotech: A Phase 3 Company Getting No Respect


IO Biotech Announces 2023 Third Quarter Results

Nov 13, 2023, 8:12 AM EST - 2 years ago

IO Biotech Announces 2023 Third Quarter Results


IO Biotech Announces 2023 Second Quarter Results

Aug 11, 2023, 8:30 AM EDT - 2 years ago

IO Biotech Announces 2023 Second Quarter Results


IO Biotech Appoints Heidi Hunter to its Board of Directors

Aug 11, 2023, 8:05 AM EDT - 2 years ago

IO Biotech Appoints Heidi Hunter to its Board of Directors


UnicornProfits
UnicornProfits Oct. 24 at 8:37 PM
What is happening to ticker CMCT right now?! CMCT is breaking out like crazy.. only 700k float Are they pumping up ticker CMCT for 300% today!? Looks like all eyes are moving to CMCT now.. Watching: $IOBT $YYAI $TOVX $BBAI -!
0 · Reply
SnoddyTradz
SnoddyTradz Oct. 24 at 7:08 PM
$IOBT $YDKG $SCNX Check out $WGRX
0 · Reply
SnoddyTradz
SnoddyTradz Oct. 24 at 4:45 PM
$IOBT $DNUT $BYND $IXHL Check out $SCNX
0 · Reply
BadyBady
BadyBady Oct. 24 at 2:45 PM
$IOBT I Believe I can Fly 😎
0 · Reply
GCPA
GCPA Oct. 24 at 2:39 PM
$IOBT Acral/mucosal Melanoma patients were 24; pre-treated were 36. A total of 60 (ab 15% of ITT). Removing pre-treated, mPFS went to 24.8 months (HR 0.74); removing acral mucosal, mPFS went to 22.3 months. Both subgroups reduced mPFS equally. To remove both altogether should increase mPFS far beyond 25 months.
1 · Reply
BadyBady
BadyBady Oct. 24 at 1:25 PM
0 · Reply
BadyBady
BadyBady Oct. 24 at 9:14 AM
0 · Reply
BadyBady
BadyBady Oct. 24 at 9:08 AM
$IOBT Amazing potential 😎❤️😍
0 · Reply
GCPA
GCPA Oct. 23 at 11:22 PM
$IOBT Seeing DOR graph (about 42% of ITT population stll in response at 18 months and curve already flat in Cyl. arm) you see that OS can be stat. sig or very very close to it, even with the few number of events pre-specified in protocol. Market has seen that. Don't think at all that the Company will end bankrupt. BUT this trial has three issues. Two that we know (narrowly missed stat. sig in PE, and just 17 US patients). And a third one that I see clearly appearing now. Hassel said it in an interview, and it was also stated in a paper @badprecog posted. MOA is not fully clear, translational analysis needed: how did the effect happen in PDL1-? It wasn't clear in Phase 1/2. And, why did it work so bad in PDL1+ if in H&N has worked so well in PDL1+ -even lung has been better? Too much noise and two subgroups to extract in a new trial: pretreated (9% of patients) and acral-mucosal (ab 5% of patients). If OS hits, may be Conditional marketing by EMA with a confirmatory trial.
1 · Reply
Nieven
Nieven Oct. 23 at 8:00 PM
0 · Reply
badprecog
badprecog Oct. 23 at 7:24 PM
$IOBT Anyone else playing around with OS data? I really don't see a scenario where we are not Stat Sig for OS.
0 · Reply
peepa
peepa Oct. 23 at 6:51 PM
$IOBT this aint going more than 1 dollar today
0 · Reply
Nieven
Nieven Oct. 23 at 6:37 PM
$IOBT nice bounce
0 · Reply
bullrider19
bullrider19 Oct. 23 at 4:43 PM
$IOBT looking for .72 again ,67% on last trade in 3days little bearish short term
0 · Reply
BadyBady
BadyBady Oct. 23 at 4:20 PM
0 · Reply
ryno5oh
ryno5oh Oct. 23 at 3:05 PM
$MSAI is on fire! $GPUS $IOBT jump ship! Come over to MSAI
0 · Reply
badprecog
badprecog Oct. 23 at 2:14 PM
$IOBT You have to figure Merck will lobby the FDA and OS being stat sig is over 70% for the whole trial and probably like 99.9999% for pdl1-negative.
0 · Reply
BobAxe
BobAxe Oct. 23 at 1:51 PM
$IOBT holding well over $1
0 · Reply
Abo_Hamza
Abo_Hamza Oct. 23 at 1:43 PM
0 · Reply
badprecog
badprecog Oct. 23 at 1:41 PM
$IOBT I wonder if we will keep following the dip then rip pattern.
0 · Reply
ArbMan
ArbMan Oct. 23 at 1:38 PM
$IOBT I am pretty shocked that FDA approved REPL after the CRL. Do we think this gives us a path at FDA too without a new phase 3? It might be hard to find out during a government shutdown.
0 · Reply
BadyBady
BadyBady Oct. 23 at 1:28 PM
$IOBT $IOBT 😎😍
0 · Reply